NCT02880293

Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor

Partially HLA-Mismatched Related Donor Hematopoietic Stem Cell Transplantation Using Killer Immunoglobulin Receptor and Human Leukocyte Antigen Based Donor Selection

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study will test whether half matched donors with favorable KIR genes will reduce the risk of cancer recurring after transplant.

Conditions

• Hematologic Malignancy

Interventions

Type	Name	Description
DRUG	melphalan	melphalan (140 mg/m2 IV on day -7)
DRUG	fludarabine	fludarabine (40 mg/m2/d on days -5 through -2)
DRUG	thiotepa	thiotepa (5 mg/kg IV on day -67)
DRUG	Cyclophosphamide	cyclophosphamide (50 mg/kg IV on day +3 and +4)
DRUG	Mesna
DRUG	Mycophenolate Mofetil	(15 mg/kg PO/IV TID)
DRUG	Filgrastim
DRUG	Tacrolimus

Timeline

• Start date: 2016-08-23
• Primary completion: 2023-11-20
• Completion: 2023-11-20
• First posted: 2016-08-26
• Last updated: 2024-12-06
• Results posted: 2024-12-06

Locations

1 site across 1 country: United States